Physician profile
Laura A Teasley
NPI 1154312635
$2,748.80
in general payments reported to CMS, 2019-2025
12 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $42.59 · 2021: $261 · 2022: $463 · 2023: $550 · 2024: $711 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $662.36 | 2019-2024 | Eylea Hd |
| Astellas Pharma US INC | $561.51 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $370.41 | 2022-2024 | Syfovre |
| Genentech USA, INC. | $247.98 | 2021-2025 | Vabysmo |
| Alimera Sciences, INC. | $197.50 | 2019-2023 | Iluvien |
| Eyepoint US, INC. | $161.18 | 2019-2022 | |
| Abbvie INC. | $151.70 | 2022-2025 | Ozurdex |
| Mallinckrodt Hospital Products INC. | $116.90 | 2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.98 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $88.72 | 2019 | |
| Allergan, INC. | $74.17 | 2019-2021 | |
| Biogen, INC. | $16.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Teasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.